In a groundbreaking real-world clinical study, researchers have unveiled compelling evidence supporting the efficacy and tolerability of low-dose tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, for inducing significant short-term weight loss in adults with obesity who do not have diabetes. Previously, tirzepatide’s impressive weight-reduction results were documented primarily in […]
